Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infection Control Clear all
Recruiting Phase 2 Interventional

Convalescent Plasma as a Possible Treatment for COVID-19

NCT04442191
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma, Placebo
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Jul 22, 2026, 12:23 AM EDT
Terminated Phase 3 Interventional Results available

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

NCT03558984
View directory record Official record
Conditions
Surgical Site Infection, Sternal Infection, Cardiac Surgery
Interventions
D-PLEX, Standard of Care
Drug · Other
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Huston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

NCT04575038
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Brequinar, Placebo
Drug
Lead sponsor
Clear Creek Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

NCT03840148
View directory record Official record
Conditions
Urinary Tract Infections, Acute Pyelonephritis
Interventions
Cefepime/VNRX-5133 (taniborbactam), Meropenem
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Buena Park, California • Chula Vista, California • La Mesa, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 22, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT06685835
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brensocatib, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Phoenix, Arizona • Sacramento, California • Coral Gables, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 12:23 AM EDT
Withdrawn Not applicable Interventional

Double-Blind Randomized Placebo-Controlled Trial of a Proprietary Full Hemp Flower Formulation for Long COVID

NCT05467904
View directory record Official record
Conditions
Post-acute COVID-19 Syndrome
Interventions
Xltranplus, Xltran
Other
Lead sponsor
LUCINDA BATEMAN, MD
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

NCT04625725
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
5,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Tempe, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

NCT04376684
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Otilimab, Placebo 1, Placebo 2, Standard of care
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

NCT01856426
View directory record Official record
Conditions
Hepatitis C
Interventions
EDP239, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 22, 2026, 12:23 AM EDT
Recruiting Not applicable Interventional

Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

NCT05471908
View directory record Official record
Conditions
Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Interventions
As-needed follow up, Automatic follow-up
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
Up to 18 Years
Enrollment
2,674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Mountain View, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Efprezimod alfa, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Not applicable Interventional

Tele-Harm Reduction

NCT05208697
View directory record Official record
Conditions
IV Drug Usage, HIV Infections, Hepatitis C
Interventions
Tele-Harm Reduction, off-site linkage
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

NCT03930615
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Letermovir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

NCT00510874
View directory record Official record
Conditions
Influenza
Interventions
Pumarix™, Pandemrix ™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 22, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

NCT04056611
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678 250 mg, Placebo, JNJ-53718678 125 mg
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
13 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Detroit, Michigan • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 22, 2026, 12:23 AM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

NCT00001058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 12:23 AM EDT
Completed No phase listed Observational

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

NCT00050063
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic vaccinations from A5058s
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

NCT00791219
View directory record Official record
Conditions
Onychomycosis
Interventions
SUBA-itraconazole, Itraconazole, Placebo
Drug
Lead sponsor
Halcygen Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Jul 22, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

NCT04396106
View directory record Official record
Conditions
COVID-19
Interventions
AT-527, Placebo
Drug · Other
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Davis, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway

NCT05467007
View directory record Official record
Conditions
Viral Infection, Acute Respiratory Infection, Upper Resp Tract Infection
Interventions
BioFire® Respiratory Panel 2.1-EZ
Diagnostic Test
Lead sponsor
Andrew Meltzer
Other
Eligibility
7 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 12:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Three Arm Trial of Immune Effects of Echinacea

NCT01129128
View directory record Official record
Conditions
Upper Respiratory Tract Infections
Interventions
Echinacea purpurea product, Placebo
Biological
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Jul 22, 2026, 12:23 AM EDT
Terminated Not applicable Interventional Results available

STIP: Statin Trial for Influenza Patients

NCT00970606
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
Interventions
Rosuvastatin (crestor), Placebo
Drug
Lead sponsor
Gordon Bernard
Other
Eligibility
13 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 22, 2026, 12:23 AM EDT
Terminated Not applicable Interventional

Adjunctive Nitrous Oxide During ED Incision and Drainage of Abscess

NCT03127371
View directory record Official record
Conditions
Abscess
Interventions
Nitrous Oxide, Oxygen
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jul 22, 2026, 12:23 AM EDT